2Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii [J].Nat Rev Microbiol,2007, 5(12) :939 - 951.
3Perez F, Hujer A M, Hujer K M, et al. Global challenge of multidrug-resistant Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2007,51 ( 10) : 347 l - 3484.
4Hoffmann M S, Eber M R, Laxminarayan R. Increasing re- sistance of Acinetobacter species to imipenem in United States hospitals, 1999- 2006[J]. Infect Control Hosp Epidemiol, 2010,131(2) : 196- 197.
7Rodriguez-Bano J, Marti S, Soto S, et al. Biofilm formation in Acinetobacterbaumannii : associated features and clinical impli- cations[J]. Clin Microbiol Infect, 2008,14 (30) :276 - 278.
8Lee H W, Koh Y M, Kim J, et al. Capacity of multidrugre sistant clinical isolates of Acinetobacter baumannii to form bio film and adhere to epithelial cell surfaces[J]. Clin Microbiol Infect, 2008,14(1) : 49 - 54.
9Niu C, Clemmer K M, Bonomo R A, etal. Isolation and char- acterization of an autoinducer synthase from Acinetobacter bau- mannii[J]. J Bacteriol,2008,190(9) =3386 - 3392.
10Dickschat J S. Quorum sensing and microbial biofilms[J]. Nat Prod Rep,2010,27(3) :343 - 369.
4PACHECO-FOWLER V, GAONKAR T, WYER P C, et al. Antiseptic impregnated endotracheal tubes for the prevention of bacterial colonization[J]. J Hosp Infect,2004,57(2) :170-174.
5COGAN N G, KEENER J P. The role of the biofilm matrix in structural development[ J ]. Math Med Biol,2004,21( 2 ) : 147-166.
6LASA I. Towards the identification of the common features of bacterial biofilm development [ J ]. Int Microbiol,2006,9 ( 1 ) :21-28.
7SOBOH F, KHOURY A E, IAMBONI A C, et al. Eeffcets of ciporfloxacin and protamine sulfate combination against catheter-associated pseudomonas aeruginosa biofilms [ J]. Antimicrob Agent Chemother, 1995,39(6) :1281-1286.
8O' TOOLE G. To build a biofilm [ J ]. J Bacteriol, 2003,185 ( 9 ) : 2687-2689.
9ANWAR H, STRAP J L, CHEN K, et al. Dynamic Tnteractions of biofilms of mucoid pseudomonas aeruginosa with tobramycin and piperacillin [ J ]. Antimicrob Agents Chemother, 1992,36 (6) : 1208-1214.
10INGLIS T J. Evidence for dynamic phenomena in residual tracheal tube biofilm[ J]. Br J Anaesth, 1993,70( 1 ) :22-24.
3Peteg A Y,Seifert H,Paterson D L.Acinetobacter baumannii:emergence of a successful pathogen[J].Clin Microbiol Rev,2008,21(3):538-582.
4Dhillon R, Clark J. Infection in the intensive care unit(ICU) E J3. Current AnaesthesiaCritical Care, 2009,20 (4) : 175 - 182.
5Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review [J]. BMC Infect Dis, 2006, 6=130.
6Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-re- sistant ( MDR), extensively drug-resistant (XDR) and pan- drug-resistant(PDR) bacteria in healtheare settings. Expert proposal for a standardized international terminology [EB/ OL]. (2010-08)[2015-3]. http..//ECDC Entwurf 2010. www. escmid. Org.
7Phumisantiphong U, Diraphat P, Utrarachkij F, et al. Clonal spread of carbapenem resistant Acinetobacter baumannii in the patients and their environment at BMA Medical College and Vajira Hospital[J]. J Med Assoc Thai, 2009, 92( Suppl 7) : $173- 180.
